Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the European Commission has granted Orphan Drug Designation (ODD) to AZP- 3601 for the treatment of hypoparathyroidism. Amolyt previously received ODD from the U.S. Food and Drug Administration for AZP-3601 for the same condition in January 2021.
